“These respected chemists will bring a tremendous amount of scientific insight to our research efforts,” said Dr. Howard Verrico, President and CEO of Sirona Biochem. “This expertise will help to streamline our processes in compound development, selection and formulation and give us a better understanding of the compounds’ commercial relevance,” Dr. Howard Verrico added.

Biography of Professor Pierre Vogel
Dr. Pierre Vogel has been a Professor of Organic Chemistry at the École Polytechnique Fédérale de Lausanne, Switzerland since 2001.  In 1969, he completed his Ph.D under the supervision of Prof. H. Prinzbach at the Institute of Organic Chemistry, University of Lausanne. Dr. Vogel spent two years at Yale University, New Haven, Connecticut, USA with Prof. Martin Saunders, Prof. J. A. Berson, K. A. Wiberg and P.v.R. Schleyer (Princeton Universtiy). He then worked as a Research chemist at Syntex S.A., in Mexico with Prof. P.Crabbé before returning to the University of Lausanne in 1973. As of 1977 he became Professor of organic chemistry at the University of Lausanne. In 1991 he was Vice-Chairman of the Institute of organic Chemistry, University of Lausanne until 2001. He was also a part-time graduate school teacher at the Universities of Rouen and Caen from 1991 to 1993 and part-time professor at Ecole Polytechnique de Palaiseau from 1993-2000. Dr. Vogel has authored over 520 publications in referred journals.

Biography of Dr. Bernard Langlois
Dr. Bernard Langlois is a scientific expert in the area of organic fluorine chemistry with more than 40 years of academic experience. Until recently, he was the Director of the SERCOF laboratory at the University of Lyon in France as well as the Research Director for CNRS at the Université de Claude Bernard. D. Langlois has been involved in organic fluorine chemistry since 1970, when he joined the research team of the Rhône-Poulenc Co.  His interest is directed to all aspects of organic fluorine chemistry; aromatic and aliphatic compounds, fluorination and trifluoromethylation techniques, as well as functionalization of fluorinated substrates.  During his career, he developed new methods for performing radical perfluoroalkylation using “Halons” or sodium trifluoromethanesulfinate, mild nucleophilic trifluoromethylation with fluoral hemiaminals or hydroxytrifluoroacetamides, as well as nucleophilic trifluoromethoxylation.  He was also involved in work on a new route to triflic acid from bromotrifluoromethane.  Dr. Langlois is the author of more than 90 articles, 9 book chapters, 33 patents, 60 poster presentations, 69 oral presentations and 39 invited and plenary lectures in national and international events. Dr. Langlois received his PhD from the University of Lyon (France).

Biography of Dr. Eric Leclerc
Dr. Eric Leclerc is currently a Centre Nationale de la Recherche Scientifique (CNRS) Researcher at the Institut Charles Gerhardt in France.  In this role, Dr. Leclerc is responsible for the development of new tools for the synthesis of fluoroolefins and metabolically stable, fluorinated glycomimetics as analogues of glycoconjugate with high therapeutic potential.  Prior to this role he was a Researcher at the Institut National des Sciences Appliquees (INSA) de Rouen, also in France, where he was responsible for the development of fluorinated glycomimetics and synthesis of chiral ligands for asymmetric catalysis. Previous positions include a post-doctoral role at the University of Hawaii at Manoa and a PhD position at the Universite Pierre et Marie Currie.  Dr. Leclerc has authored more than 20 publications and has given several presentations in the area of fluorinated glycomimetics.  He received his PhD and Masters in organic chemistry from the Universite Pierre et Marie Currie in 2001 and 1997, respectively.

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging cosmeceuticals and biological ingredients.  We are applying a proprietary chemistry technique to improve the pharmaceutical properties of our carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone:  604.282.6065
Email: jjang@sironabiochem.com

———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.  Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

In the study, Sirona Biochem’s inducer produced more protein compared to a leading commercially available inducer at the same concentration. In addition, Sirona Biochem’s compound induced synthesis of a soluble recombinant protein in Escherichia coli for up to 24 hours. 

“We believe we are on track to producing an inducer that is more stable, can be stored at room temperature and can improve protein yields for recombinant protein manufacturers, which could be particularly useful in producing insulin,” said Sean Cunliffe, Chief Business Officer of Sirona Biochem “The results of this study further validates our proprietary chemistry platform and its potential in improving upon existing carbohydrate molecules,” Mr. Cunliffe added.

Inducers are carbohydrates which trigger recombinant protein production. The quality of the inducer is key to the production process and can affect the quality and yield of the protein. Current inducers, because they are carbohydrates, are metabolically unstable, and require special handling conditions.

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients.  The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone:  604.282.6065
Email: jjang@sironabiochem.com

———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.  Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

February 24, 2010.

            Number of Warrants:                             400,000
            Original Expiry Date of Warrants:           February 24, 2012
            New Expiry Date of Warrants:                February 24, 2013
            Exercise Price of Warrants:                    $0.40

October 23, 2010. 

            Number of Warrants:                             10,215,000
            Original Expiry Date of Warrants:           October 23, 2012
            New Expiry Date of Warrants:                October 23, 2013
            Exercise Price of Warrants:                    $0.20

All other terms of the February 2010 Warrants and October 2010 Warrants remain unchanged.

Please see the news release issued on January 29, 2010 and August 25, 2010 for further details.

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients.  The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of our carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone:  604.282.6065
Email: jjang@sironabiochem.com

———————————————

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business

“Sean Cunliffe brings a wealth of biotechnology and pharmaceutical executive experience and has been a key player in negotiating major pharmaceutical partnerships,” said Dr. Howard Verrico, President & CEO of Sirona Biochem.  “We are thrilled to welcome Sean to Sirona Biochem and know his talent comes at the right time for our company as our programs mature to a partner-ready stage,” Dr. Verrico added.

Sirona Boiochem Corp. has granted a total of 2,000,000 stock options pursuant to the company’s stock option plan. These options expire in five years, have an exercise price of $0.12 cents per share and are subject to vesting. These options are granted to Sean Cunliffe in connection with his appointment as Chief Business Officer and appointment to the board of directors. These options and the board of director appointment are subject to receipt of all necessary regulatory approvals.

About Sean Cunliffe
Mr. Sean Cunliffe has more than 25 years of pharmaceutical marketing and sales experience in a wide variety of therapeutic areas.  Most recently, he was Senior Vice President of Sales and Marketing at Angiotech Pharmaceuticals. Prior to Angiotech, Mr. Cunliffe served as Chief Commercial Officer of Neuromed Pharmaceuticals, now Zalicus Inc.  At Neuromed, Mr. Cunliffe negotiated, from ALZA Corporation, the in-licensing of a once-daily hydromorphone, now marketed as Exalgo®.  He also negotiated a partnership and research collaboration with Merck, in what was noted at the time as the largest pharmaceutical deal in Canadian history.  Mr. Cunliffe has held several leadership roles at Wyeth Pharmaceuticals in Collegeville, PA,  including Vice President of New Product Marketing where he co-chaired, along with Discovery, both the Neuroscience and Cardiovascular leadership teams, Vice President Marketing and Global Business Manager of Neuroscience and Vice President of Cardiovascular and Gastrointestinal Marketing. Prior to Wyeth, he was the Group Director U.S. Marketing, Gastrointestinal and Anti-Viral Products at Glaxo Wellcome in Research Triangle Park, NC. Mr. Cunliffe also served for Glaxo and Astra Pharmaceuticals in a variety of sales and marketing roles in Canada before moving to the US to work in both global and US domestic commercial functions. Mr. Cunliffe received an MBA in Finance from McMaster University in Hamilton, Ontario and an Honours B.Sc. in Biology from Queen’s University in Kingston, Ontario.

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, depigmenting and anti-aging agents for cosmetic use and biological ingredients.  The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone:  604.282.6065
Email: jjang@sironabiochem.com

———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.  Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

“We thank Mark for his commitment and contributions over the past three years.  He has been instrumental in building the Company to its current stage.  The Company has five major projects that have evolved and will be taken to the next level.  We greatly appreciate Mark’s efforts and wish him all the best in his future endeavours,” said Dr. Howard Verrico, Chief Executive Officer of Sirona Biochem.  Dr. Verrico will, for the time being, take on the role of President in addition to his position as Chief Executive Officer of the Company.

Mark Senner joined Sirona Biochem in 2009. During his tenure, the Company completed its public listing on the TSX-Venture Exchange, acquired French-based TFChem and went from a single product emerging biotech company to that of a platform based technology company focused on fluorinated carbohydrate chemistry.  Previously, he held positions at Biovail, Merck Frosst Canada, Bristol-Myers Squibb, Solvay and Novartis.

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients.  The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of our carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone:  604.282.6065
Email: jjang@sironabiochem.com

———————————————

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.  Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

The $1.9-million grant was provided by France’s Ministry of Economy, Finance and Industry. TFChem is currently developing a potentially new safe and effective depigmenting agent that can be used in creams and other cosmetic applications to lighten and evenly tone skin.

“These funds will allow our team to bring our depigmenting agent to a commercially-ready stage,” said Dr. Howard Verrico, CEO of Sirona Biochem. “The grant is also a testament to the quality of Sirona’s chemistry technology and its application to the multi-billion dollar cosmeceutical industry.”

The global market for skin brighteners is rapidly growing, with Japan leading demand for this cosmetic segment. By 2012, sales of skin lightening products are estimated to reach $2 billion in the Asia Pacific region alone. Experts estimate that the market will exceed $10 billion globally by 2015.

Skin lightening products are also a fast emerging market in North America and Europe where demand has been mainly driven by a desire to reverse sun damage, treat skin-related diseases such as vitiligo and to minimize the appearance of sun spots and freckles.

TFChem has assembled a consortium of partners dedicated to advancing the company’s depigmenting agent. The consortium – which includes the University of Rouen, contract research organization Biogalénys and Sirona Biochem’s subsidiary, TFChem – will split the grant funding based on specific guidelines set out by the French government. Funds will be distributed by the French government over the remainder of the project, which is expected to span three years.

The French government is looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation. Projects must involve one or several competitiveness clusters.

TFChem’s project involves Cosmetic Valley – an innovation cluster located just west of Paris, France that is dedicated to the research and development of innovative cosmetic products.  

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients.  The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of our carbohydrate-based molecules. For more information visit www.sironabiochem.com.

This project is cofinanced by the European Union.  Europe witnesses in Haute-Normandie with the support of European Regional Development Fund (E.R.D.F.).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###

Media contact
Julie Jang
Director, Communications
Sirona Biochem Corp.
604.282.6065
jjang@sironabiochem.com

Investor contact
Gord Zelko
Lakeshore Capital Corp.
778.437.2237
gord@lakeshorecapitalcorp.ca

———————————————

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.  Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients.  We are applying a proprietary chemistry technique to improve the pharmaceutical properties of our carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone:  604.282.6065
Email: jjang@sironabiochem.com

———————————————

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.  Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

“Our acquisition of France-based TFChem earlier this year has given us new and exciting programs to pursue such as cosmetic agents and a cancer vaccine antigen,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We are focused on developing and validating this newly-acquired proprietary platform technology and applying it to a diverse portfolio that offers attractive market potential and value,” he added.

Research & Development Update
Sirona Biochem’s lead product, a sodium glucose transporter (SGLT) inhibitor for Type 2 diabetes, recently achieved positive results.  Preclinical studies of the Company’s SGLT inhibitor are ongoing and the Company expects to have efficacy, safety and toxicity results in the next few months.  Results from those studies will be released once they are conclusive. 

Sirona Biochem also recently announced the development of its Cancer Vaccine Antigen project.  This project has become a high priority and the Company is accelerating development of this program by allocating more resources to it. 

To enable partnership and commercial plans, Sirona Biochem is refining the depigmenting agent program this fall with its newly-assembled consortium partners. Studies of the Company’s biological inducers are also being conducted.  The Company is aiming to provide conclusive results from these studies in the next few months.  These studies, as well as the recent positive preclinical results, will help to further validate the Company’s proprietary chemistry platform and its ability to produce carbohydrate compounds with greater stability, selectivity, bioavailability and efficacy.

Post-acquisition update
Since the acquisition of TFChem, Sirona Biochem has been evaluating its resources and building its infrastructure with a goal to remain efficient and on target with R&D objectives. These efforts include sourcing competent contract research organizations with a proven track record to analyze the Company’s molecules, streamlining processes and implementing cost-effective and efficient technologies.  On an ongoing basis, Sirona Biochem has been engaging with experts in the field and will be adding new consultants and advisors to advance its programs.  The Company has reviewed its patent strategy with French intellectual property law firm Cabinet Regimbeau in Paris to ensure all necessary steps are being taken to protect its unique molecules.  Sirona Biochem recognizes that securing patent protection for its research is essential to capitalize on the Company’s achievements.

New Programs
From very early on in Sirona Biochem’s acquisition efforts, the Company recognized the value of TFChem’s proprietary chemistry technology and its application opportunities.  Of particular interest was the Cosmeceuticals program.  Large market potential, lower development costs and shorter development timelines make this an attractive, lower risk program.  Since acquiring TFChem, the Company has been engaging with experts in the field to understand how best to apply its technology and optimize development efforts.  Bringing in experts, such as world-renowned dermatologist Dr. Stuart Maddin, helps to ensure Sirona Biochem is conducting the right research and targeting worthwhile markets.  Two specific cosmeceutical programs the Company is developing are depigmenting agents and anti-aging compounds.

Another new program Sirona Biochem is pursuing is a cancer vaccine antigen, which is a project TFChem founder, Dr. Geraldine Deliencourt-Godefroy, has been developing for many years.  

The Company’s proprietary technology continues to strengthen and the Sirona Biochem management team has been impressed with the scientific expertise of the TFChem chemists and the breakthroughs they have made in carbohydrate chemistry. 

Partnership update
Sirona Biochem has been attending pharmaceutical conferences and meeting with pharmaceutical partners over the last few months and are planning for follow-up meetings after the results of its additional preclinical tests. The Company plans to complete preclinical studies for its SGLT inhibitor program and seek a partner for clinical and commercial development.  Cosmetic, vaccine and biotechnology partners are also being evaluated for each respective program.  In addition to research and development partners, Sirona Biochem recently sponsored the Canadian Diabetes Association.  Given the shared vision of improving the lives of those living with diabetes, the partnership was beneficial for both parties.

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients.  We are applying a proprietary chemistry technique to improve the pharmaceutical properties of our carbohydrate-based molecules.    For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone:  604.282.6065
Email: jjang@sironabiochem.com

———————————————

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.  Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients.  We are applying a proprietary chemistry technique to improve the pharmaceutical properties of our carbohydrate-based molecules.  For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone:  604.282.6065
Email: jjang@sironabiochem.com
———————————————

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.  Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.